-
Phenothiazines Activate Macrophage Antibacterial Defenses
2026-09-24
A 2025 study reports that phenothiazines strengthen macrophage antibacterial activity alongside increased lysosomal activity, reactive oxygen species (ROS), and autophagy. Inhibiting autophagy or scavenging ROS weakened this effect, while perphenazine reduced lesions and inflammation in a mouse model of Salmonella Typhimurium infection, supporting further investigation of host-directed therapy.
-
Membrane Repair and Cytokine Control in Liver Infection
2026-09-24
A study of TMEM16F in Kupffer cells reframes liver infection around membrane integrity, cell survival, inflammation, and metabolism. This article explores how Ac-YVAD-CMK can help translational researchers test a distinct, caspase-1-dependent cytokine-processing hypothesis—without confusing it with the membrane-repair mechanism established by the study.
-
Novel PDK4 Inhibitors: Evidence for Compound 8c
2026-09-23
The study reports an anthraquinone-derived allosteric inhibitor series and identifies compound 8c, which inhibited PDK4 in vitro with an IC50 of 84 nM. Findings in mouse models and cancer-related cellular assays support further investigation, while leaving important questions about selectivity, dosing, and translation to human disease unresolved.
-
Coelenterazine: From ROS Signals to Translation
2026-09-23
Coelenterazine can connect luciferase reporting with reactive oxygen species biology, offering translational researchers a way to interrogate endocrine, renal, oxidative-stress, and cancer-associated pathways while controlling for substrate chemistry, solvent effects, and reporter-specific confounders.
-
qPCR Quantification of Moloney Murine Leukemia Virus
2026-09-22
Choi, Murphy, and Nitta developed a real-time PCR assay that targets a packaging signal–gag region to quantify exogenous Moloney murine leukemia virus while reducing interference from endogenous retroviral sequences. The method detected viral sequences in infected mouse cells across a 16–72-hour post-infection window and provides a faster, scalable molecular complement to focal immunofluorescence assays.
-
Thioredoxin Control of CHK1 Inhibitor Sensitivity
2026-09-22
The reference study identifies the thioredoxin system as a determinant of CHK1 inhibitor response in non-small cell lung cancer. Its central advance is linking Trx1-dependent redox recycling of RRM1 to ribonucleotide reductase activity, deoxynucleotide availability, replication stress, and the therapeutic synergy between CHK1 and thioredoxin reductase inhibition.
-
BX795: PDK1 Inhibitor Mechanism and Evidence
2026-09-21
BX795 is an ATP-competitive PDK1 inhibitor with additional TBK1 and IKKε activity. Its nanomolar biochemical potency, micromolar cancer-cell growth inhibition, and use in IRF3-linked innate immune assays make it a versatile research probe rather than a pathway-specific therapeutic.
-
BX795: A Mechanism-First PDK1 Inhibitor Guide
2026-09-21
BX795 is a PDK1 inhibitor whose parallel TBK1 and IKKε activity makes assay interpretation more complex—and more informative. This mechanism-first guide connects kinase engagement, IRF3 signaling, autophagy, and cancer-cell phenotypes to practical experimental decisions.
-
Oxaliplatin A8648: Reproducible Cytotoxicity Assays
2026-09-20
Learn how Oxaliplatin (SKU A8648) can address common variability in cell viability, proliferation, and cytotoxicity workflows through mechanism-aware design, controlled preparation, and appropriate interpretation. Scenario-based guidance connects DNA adduct formation, apoptosis induction via DNA damage, resistance biology, and practical product selection.
-
Solanesol B8776: Practical Workflow and QC Guide
2026-09-19
Solanesol B8776 is a hydrophobic polyisoprenoid alcohol for controlled biochemical and membrane-related workflows where solvent compatibility is critical. This guide covers DMSO preparation, storage, controls, and troubleshooting, while defining why water- and ethanol-based systems and diagnostic or medical use are inappropriate.
-
Liproxstatin-1 as a Ferroptosis Assay Discriminator
2026-09-18
Liproxstatin-1 is a ferroptosis inhibitor that helps researchers distinguish lipid-peroxidation-driven death from broader oxidative or apoptotic injury. This article connects its rescue logic to emerging PPZ1-TORC1 findings in Candida albicans and shows how to design more causally informative assays.
-
Pam3CSK4 TFA: TLR1/2 Activation Workflows
2026-09-18
Pam3CSK4 TFA provides a defined, synthetic stimulus for dissecting TLR1/2-driven cytokine responses without the biological variability of whole-bacterium preparations. This workflow-focused guide shows how to use it for ex vivo immune profiling, dose optimization, comparative receptor studies, and carefully controlled in vivo TLR1/2 activation.
-
Cy5 hydrazide for Carbonyl Labeling
2026-09-17
Cy5 hydrazide enables sensitive carbonyl-selective fluorescence for oxidized proteins, periodate-activated glycoproteins, aldehyde-bearing oligonucleotides, and nanoparticle interface studies. This guide combines practical labeling conditions with controls that separate covalent biomolecule labeling from nonspecific particle association.
-
Sulfaphenazole: CYP2C9 Inhibitor Workflows
2026-09-17
Sulfaphenazole is a practical CYP2C9 inhibitor for connecting drug-metabolism experiments with vascular, oxidative-stress, wound-healing, and antibacterial models. This workflow-focused guide covers solvent handling, assay design, translational readouts, and troubleshooting for reproducible use.
-
Clarithromycin: A Strategic CYP3A DDI Tool
2026-09-16
A translational framework for using Clarithromycin as a mechanistically defined CYP3A inhibitor in drug-drug interaction research, pharmacokinetic studies, statin metabolism interaction programs, and cardiovascular development.